Corporate News 06/04/2012
Bad Vilbel, June 4, 2012 – The STADA sales companies STADApharm GmbH, ALIUD PHARMA GmbH and cell pharm Gesellschaft für pharmazeutische und diagnostische Präparate mbH were very successful in the second round of tenders of Barmer GEK for discount agreements pursuant to Section 130 a SGB V valid throughout Germany.
In the framework of this most recent Barmer GEK round with a total tender volume of approximately Euro 408 million, the three STADA sales companies were able to conclude contracts for a total of 13 active ingredients with Barmer GEK, the largest German public health insurance organization, in which about 8.7 million of the patients covered by state insurance in Germany are members.
Nine of the active ingredients awarded are thereby accounted for by STADApharm, three active ingredients by ALIUD PHARMA and one active ingredient by cell pharm. The contracts are legally effective, start on August 1, 2012 and have a regular term of two years. Each respective STADA sales company acts as the single contract partner (single source) for the individual awards.
In light of all the discount agreements signed over recent months, among others in the context of the recent 8th AOK tender round, the STADA Executive Board continues to expect that the Group’s market share by volume in the German market will increase further. STADA’s market share by volume in the first quarter of 2012 amounted to approximately 13.4 percent and was thus one percent above the corresponding period of the previous year of approximately 12.4 percent.
For more information, please contact:
STADA Arzneimittel AG
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506